TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Wall Street NYSE Lead
Play
JIM CRAMER

Game Plan: Cramer's 'Mad Money' Recap (Friday 9/11/20)

PRESS RELEASES

Great Place To Work Names Horizon Therapeutics Plc To Best Workplaces For Parents List

PRESS RELEASES

Horizon Therapeutics Plc Donates Additional $1.2 Million To Support COVID-19 Relief Efforts In Illinois And Other Impacted U.S. And International Communities

PRESS RELEASES

Horizon Therapeutics Plc To Participate In Upcoming Investor Conferences

PRESS RELEASES

Horizon Therapeutics Plc And Halozyme Therapeutics, Inc. Enter Global Collaboration And License Agreement For ENHANZE® Technology

PRESS RELEASES

Horizon Therapeutics Plc And Halozyme Therapeutics, Inc. Enter Global Collaboration And License Agreement For ENHANZE® Technology

PRESS RELEASES

First Thyroid Eye Disease (TED) Awareness Week To Increase Education And Understanding Of Vision-Threatening Disease

PRESS RELEASES

New Data Build On Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy In Thyroid Eye Disease (TED), Including In Patients With Less Severe Disease And Longer Disease Duration

PRESS RELEASES

Horizon Therapeutics Plc CEO Tim Walbert Honored With RARE Champion Award At Global Genes Champions Of Hope Gala

PRESS RELEASES

Horizon Therapeutics Plc To Participate In Upcoming Investor Conferences

PRESS RELEASES

Higher Response Rates In RECIPE Randomized Controlled Trial Of KRYSTEXXA® (pegloticase Injection) Concomitantly Used With The Immunomodulator Mycophenolate Mofetil

PRESS RELEASES

Karin Rosén, M.D., Ph.D. (Photo: Business Wire)

PRESS RELEASES

Chicago Tribune Names Horizon Therapeutics A 2020 Top Workplace For The Sixth Consecutive Year

PRESS RELEASES

New TEPEZZA® (teprotumumab-trbw) Data To Be Presented At The American Academy Of Ophthalmology 2020 Annual Meeting

PRESS RELEASES

AGC Biologics And Horizon Therapeutics Plc Expand Partnership

PRESS RELEASES

Horizon Therapeutics Plc Initiates Clinical Trial To Assess Shorter Infusion Duration For KRYSTEXXA® (pegloticase Injection) Concomitantly Used With Methotrexate To Treat Uncontrolled Gout

PRESS RELEASES

Horizon Therapeutics Plc Named One Of The Most Innovative Companies By Crain's Chicago Business

PRESS RELEASES

Horizon Therapeutics Plc Named One Of The Best Adoption-Friendly Workplaces By The Dave Thomas Foundation For Adoption

PRESS RELEASES

New Data Offers Insights On Treatment With KRYSTEXXA® (pegloticase Injection) Among Kidney Transplant Patients For The Management Of Uncontrolled Gout

PRESS RELEASES

Horizon Therapeutics Plc Announces TEPEZZA® (teprotumumab-trbw) Selected As A Winner Of The Chicago Innovation Award

PRESS RELEASES

FORTUNE And Great Place To Work® Name Horizon Therapeutics Plc To Best Medium Workplaces List For Fifth Consecutive Year

PRESS RELEASES

TEPEZZA® (teprotumumab-trbw) Data From The Phase 2 Clinical Trial Evaluate Longer-Term Responses In People Living With Thyroid Eye Disease (TED)

PRESS RELEASES

New Data Evaluating KRYSTEXXA® (pegloticase Injection) With Concomitant Immunomodulation To Be Presented At The American College Of Rheumatology Convergence 2020

PRESS RELEASES

Horizon Therapeutics Plc To Release Third-Quarter 2020 Financial Results And Host Webcast On Nov. 2, 2020

PRESS RELEASES

Horizon Therapeutics Plc Named One Of San Francisco Bay Area's Best And Brightest Companies To Work For